IntelGenx Technologies Corp. (TSX: IGX) (OTCQB: IGXT), a leading drug delivery company focused on the development and manufacturing of pharmaceutical films, reported financial results on Thursday afternoon for the third quarter ended September 30, 2021.
2021 Third Quarter Financial Summary
- Revenue was $593,000, compared to $510,000 in the 2020 third quarter. The change is mainly attributable to increases in sales milestone revenues of $320,000, product revenues of $70,000, partially offset by a $308,000 decrease in revenues from licensing agreements.
- Adjusted EBITDA loss was $1.4 million, compared to $1.2 million in the 2020 third quarter.
- Operating costs and expenses were $2.2 million for the third quarter of 2021, versus $1.9 million for the corresponding three-month period of 2020. The increase is mainly attributable to increases of $26,000 in R&D expense, $255,000 in manufacturing expenses, $37,000 in selling, …